The FDA has approved the Paradise Ultrasound Renal Denervation system for treating hypertension. The approval was based on positive reviews by the FDA's Circulatory Systems Device panel. Data from the RADIANCE program and trials supported the approval. Renal denervation is an adjunctive treatment option for hypertension control when lifestyle changes and medication are insufficient. The system delivers ultrasound energy to denervate sympathetic nerves around renal arteries, reducing hypertension. The Paradise system offers significant blood pressure reductions and is beneficial for patients with resistant or mild to moderate hypertension.
Na inny język
z treści źródłowej
www.medscape.com
Kluczowe wnioski z
by Susan Jeffre... o www.medscape.com 11-08-2023
https://www.medscape.com/viewarticle/998237Głębsze pytania